dr. o'regan on impact of targeted agents in her2 breast cancer
Published 5 years ago • 132 plays • Length 0:52Download video MP4
Download video MP3
Similar videos
-
1:29
dr. geyer on impact of targeted agents in her2 breast cancer
-
1:10
dr. o'regan on future of chemotherapy in breast cancer
-
0:49
dr. o’regan on prognostic value of pcr in her2 breast cancer
-
0:54
dr. o’regan discusses updates in her2-positive breast cancer
-
1:11
dr. o'regan discusses the future of treatment in her2 breast cancer
-
0:49
dr. o'regan on biomarker research in breast cancer
-
1:23
dr. o'regan on endocrine therapy resistance in breast cancer
-
2:24
breast cancer risk assessment: a vital tool for women
-
1:21
dr. o'regan on treatment of breast cancer in premenopausal women
-
1:01
dr. o’regan on biosimilar education in breast cancer
-
17:53
er-signaling in her2-postive breast cancer - dr. ruth o'regan
-
1:05
dr. o’regan on the mechanism of action of trastuzumab
-
1:10
dr. o'regan discusses belle-3 study in breast cancer
-
18:25
dr. o'regan on breast cancer treatment considerations during the covid-19 crisis
-
1:17
dr. o’regan on the utility of cdk4/6 inhibitors in breast cancer
-
1:13
dr. o'regan on emerging cdk4/6 combinations in breast cancer
-
1:42
dr. o'regan on biomarkers of response to cdk4/6 inhibitors in breast cancer
-
1:37
dr. bhave on promising anti-her2 agents in her2 breast cancer
-
1:39
dr. hurvitz on the lack of predictive biomarkers in her2 breast cancer